Apnimed (APMD) vs Lexicon Pharmaceuticals (LXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Apnimed is the larger company by market cap ($771.0 million vs $747.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APMD | LXRX |
|---|---|---|
| Share price | $18.52 | $1.68 |
| Market cap | $771.00M | $747.53M |
| 1-day change | +1.65% | -4.55% |
| YTD return | — | +53.04% |
| 1-year return | — | +23.08% |
| 5-year return | — | -71.43% |
| P/E ratio (TTM) | 2.57 | — |
| EPS (TTM) | $7.22 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.29 | $2.68 |
| 52-week low | $16.12 | $1.10 |
| Distance from 52-week high | -47.52% | -37.31% |
| Analyst consensus | none | buy |
| Avg. price target upside | +171.76% | +170.83% |
| Average volume | 552.07K | 2.90M |
| Shares outstanding | 41.63M | 444.96M |
| Employees | 81 | 81 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Apnimed
APMD stock →Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
About Lexicon Pharmaceuticals
LXRX stock →Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 81 employees
APMD vs LXRX FAQ
Which is bigger, Apnimed or Lexicon Pharmaceuticals?
Apnimed (APMD) is larger, with a market capitalization of $771.00M compared with $747.53M for Lexicon Pharmaceuticals (LXRX).
Are Apnimed and Lexicon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.